T2DM patients treated with exenatide are more likely to achieve tight glycaemic control plus a more favourable metabolic profile

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1642, 2008-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A fixed combination of rosiglitazone plus metformin improves glycaemic control and cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM)

By  

Inpharma, Vol. 1, Iss. 1546, 2006-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Exenatide an excellent option for T2DM

By  

Inpharma, Vol. 1, Iss. 1553, 2006-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Pioglitazone provides greater long-term glycaemic control than glibenclamide [glyburide] in patients with type 2 diabetes mellitus (T2DM)

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Exenatide effective adjuvant to thiazolidinedione therapy for T2DM

By  

Inpharma, Vol. 1, Iss. 1586, 2007-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Insulin: basal-bolus more cost effective than premixed for T2DM

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 634, 2011-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite